Jorge Antonio Elias Godoy Carlos

Jorge Antonio Elias Godoy Carlos

Auto-generated profile, based on publicly available information

Jorge Antonio Elias Godoy Carlos

Biomedical Science Institute, Department of Pharmacology, University of Sao Paulo (USP), Sao Paulo, Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KWKaroline Barros Waitman
Karoline Barros Waitman
LALarissa C. de Almeida
Larissa C. de Almeida
MPMarina C. Primi
Marina C. Primi
JCJorge A.E.G. Carlos
Jorge A.E.G. Carlos
CRClaudia Ruiz
Claudia Ruiz
Roberto Parise-FilhoRoberto Parise-Filho
Roberto Parise-Filho

7 September 2024 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
JCJorge Antonio Elias Godoy Carlos
Jorge Antonio Elias Godoy Carlos
KLKeli Lima
Keli Lima
EREduardo Magalhães Rego
Eduardo Magalhães Rego
LCLeticia Veras Costa-Lotufo
Leticia Veras Costa-Lotufo
JMJoão Agostinho Machado-Neto
João Agostinho Machado-Neto
The central role of the control of apoptosis in the pathophysiology of Philadelphia chromosome-negative myeloproliferative neoplasms has recently been reinforced in genetic and pharmacological studies. The inhibitor of apoptosis protein family has eight members and plays an important role in apoptosis, with the most studied being survivin (BIRC5) and Xlinked inhibitor of apoptosis (XIAP). YM155 is a small molecule with antineoplastic potential that has been described as a suppressant of survivin and XIAP. In the present study, BIRC5 expression was significantly increased in primary myelofibrosis patients compared to healthy donors. On the other hand, XIAP expression was reduced in myeloproliferative neoplasms patients. In JAK2 V617F cells, YM155 reduces cell viability and autonomous clonal growth and induces apoptosis, cell cycle arrest, and autophagy. HEL cells that show greater malignancy are more sensitive to the drug than SET2 cells. In the molecular scenario, YM155 modulates apoptosis-, cell cycle-, DNA damage- and autophagy-related genes. Protein expression analysis corroborates the observed cellular phenotype and exploratory gene expression findings. In summary, our results indicate that survivin/BIRC5 and XIAP are differently expressed in myeloproliferative neoplasms and YM155 has multiple antineoplastic effects on JAK2 V617F cells suggesting that inhibitor of apoptosis proteins may be a target for pharmacological interventions in the treatment of these diseases. (c) 2024 Associa & ccedil;& atilde;o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa & ntilde;a, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

28 August 2025 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
KWKaroline Barros Waitman
Karoline Barros Waitman
HMHolli-Joi Martin
Holli-Joi Martin
JCJorge A.E.G. Carlos
Jorge A.E.G. Carlos
RBRodolpho C. Braga
Rodolpho C. Braga
VSVinícius A.M. Souza
Vinícius A.M. Souza
EMEugene Muratov
Eugene Muratov

5 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
KWKaroline Barros Waitman
Karoline Barros Waitman
HSHolli-Joi Sullivan
Holli-Joi Sullivan
JCJorge A. E. G. Carlos
Jorge A. E. G. Carlos
RBRodolpho C. Braga
Rodolpho C. Braga
VSVinícius A. M. Souza
Vinícius A. M. Souza
EMEugene Muratov
Eugene Muratov
Hematological cancer treatment with hybrid kinase/HDAC inhibitors is a novel strategy to overcome the challenge of acquired resistance to drugs. We collected IC 50 datasets from the ChEMBL database for 13 cancer cell lines (72 h cytotoxicity, measured by MTT), known inhibitors for 38 kinases, and 10 HDACs isoforms, that we identified by target fishing and literature review. The data was subjected to rigorous biological and chemical curation leaving the final datasets ranging from 76 to 8173 compounds depending on the target. We generated Random Forest classification models, whereby 14 showed greater than 80% predictability after 5-fold external cross-validation. We screened 30 hybrid kinase/HDAC inhibitor analogs through each of these models. Fragment-contribution maps were constructed to aid the understanding of SARs and the optimization of these compounds as selective kinase/HDAC inhibitors for cancer treatment. Among the predicted compounds, 9 representative hybrids were synthesized and subjected to biological evaluation to validate the models. We observed high hit rates after biological testing for the following models: K562 (62.5%), MV4-11 (75.0%), MM1S (100%), NB-4 (62.5%), U937 (75.0), and HDAC6 (86.0%). This aided the identification of 6b and 6k as potent anticancer inhibitors with IC 50 of 0.2-0.8 µM in three cancer cell lines, linked to HDAC6 inhibition below 2 nM, and blockade of AKT2 phosphorylation at 2 μM, validating the ability of our models to predict novel drug candidates. Graphical Highlights: Novel kinase/HDAC inhibitors for cancer treatment were found using machine learning 61 QSAR models for hematological cancers and its targets were built and validated K562, MV4-11, MM1S, NB-4, U937, and HDAC6 models had hit rates above 62.5% in tests 6b and 6k presented potent IC 50 of 0.2-0.8 µM in three cancer cell lines 6b and 6k inhibited HDAC6 below 2 nM, and blockade of AKT2 phosphorylation at 2 μM

5 April 2025 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
AGAnali Del Milagro Bernabe Garnique
Anali Del Milagro Bernabe Garnique
JCJorge Antonio Elias Godoy Carlos
Jorge Antonio Elias Godoy Carlos
NPNatalia Sudan Parducci
Natalia Sudan Parducci
MTMaurício Tavares
Maurício Tavares
KWKaroline Barros Waitman
Karoline Barros Waitman
JMJoão Agostinho Machado-Neto
João Agostinho Machado-Neto